Hemogenyx Pharmaceuticals, a biotech developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, has entered into a collaboration with major U.S. biotechnology company in a deal worth up to approximately $250,000 for Hemogenyx, the company said. The collaboration follows on from the announcement made by the company recently, which confirmed the filing of a provisional patent application relating to the company’s developme...